Idibell

IDIBELL has added a new scientific platform which increases applications of Biomark, an equipment purchased a year ago that performs real-time PCR, gene expression, genotyping, and digital analysis of a large number of samples. The new platform, called Access Array System, enables to obtain the number of PCR amplifications needed to sequence the samples with the new technology Next Generation Sequencing System with a great reduction of time and costs.

During the process of immune recognition, T cells and antigen-presenting cells exchange genetic information (microRNA), which allows modify the immune behavior. The researcher of the institute of health research of La Princesa Hospital, in Madrid, Francisco Sánchez-Madrid explained his recent work on processes that lead to the immune response during an IDIBELL seminar on 3rd June in the conference hall of the Duran i Reynals Hospital (ICO).

Patients with aphasia (loss of ability to understand or produce language) are able to recover language skills through the same mechanisms that allow children to learn to speak. Complex activity About Dobel

The Princes of Asturias receive the recipients of the aids in the Palacio de la Zarzuela The research group of neurometabolic diseases of IDIBELL led by the ICREA researcher Aurora Pujol will receive a grant of 45,000 euros for a research project on X -linked adrenoleukodystrophy.

The researcher Gianluigi Giannelli of the University of Bari, Italy, focuses its research on studying the molecular mechanisms responsible for the progression of tumors, especially hepatic ones, and the identification of new therapeutic targets. Giannelli explained at a conference in the framework of the seminars IDIBELL, on 20 May that this must be the correct

An international study led by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) has identified a new gene involved in susceptibility of developing breast cancer. Article’s reference Evidence for a link between TNFRSF11A and risk of Breast Cancer.

IDIBELL researchers demonstrate for the first time that inhibition of NADPH oxidases pathway slows the growth of tumor cells in vitro A study realized by researchers at the IDIBEL has shown that a drug that is under evaluation for cardiovascular disease, VAS2870, inhibits in vitro the enzymes of the family of NADPH oxidases in liver tumor cells. So it is able to reduce cell growth and regain the ability of the cell to self-destruct (apoptosis) in response to TGF-beta factor. The study results were published at the journal Biochemical Pharmacology. NADPH oxidases Article reference

“La nueva Ley de Ciencia nace sin presupuesto”